Ong Eugenia Z, Kalimuddin Shirin, Chia Wen Chong, Ooi Sarah H, Koh Clara Wt, Tan Hwee Cheng, Zhang Summer L, Low Jenny G, Ooi Eng Eong, Chan Kuan Rong
Viral Research and Experimental Medicine Center, SingHealth Duke-NUS Academic Medical Centre (ViREMiCS), 169856 Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, 169857 Singapore.
Program in Emerging Infectious Diseases, Duke-NUS Medical School, 169857 Singapore; Department of Infectious Diseases, Singapore General Hospital, 169608 Singapore.
EBioMedicine. 2021 Mar;65:103262. doi: 10.1016/j.ebiom.2021.103262. Epub 2021 Mar 7.
The coronavirus disease-19 (COVID-19) pandemic has cost lives and economic hardships globally. Various studies have found a number of different factors, such as hyperinflammation and exhausted/suppressed T cell responses to the etiological SARS coronavirus-2 (SARS-CoV-2), being associated with severe COVID-19. However, sieving the causative from associative factors of respiratory dysfunction has remained rudimentary.
We postulated that the host responses causative of respiratory dysfunction would track most closely with disease progression and resolution and thus be differentiated from other factors that are statistically associated with but not causative of severe COVID-19. To track the temporal dynamics of the host responses involved, we examined the changes in gene expression in whole blood of 6 severe and 4 non-severe COVID-19 patients across 15 different timepoints spanning the nadir of respiratory function.
We found that neutrophil activation but not type I interferon signaling transcripts tracked most closely with disease progression and resolution. Moreover, transcripts encoding for protein phosphorylation, particularly the serine-threonine kinases, many of which have known T cell proliferation and activation functions, were increased after and may thus contribute to the upswing of respiratory function. Notably, these associative genes were targeted by dexamethasone, but not methylprednisolone, which is consistent with efficacy outcomes in clinical trials.
Our findings suggest neutrophil activation as a critical factor of respiratory dysfunction in COVID-19. Drugs that target this pathway could be potentially repurposed for the treatment of severe COVID-19.
This study was sponsored in part by a generous gift from The Hour Glass. EEO and JGL are funded by the National Medical Research Council of Singapore, through the Clinician Scientist Awards awarded by the National Research Foundation of Singapore.
2019冠状病毒病(COVID-19)大流行在全球范围内造成了生命损失和经济困难。多项研究发现了许多不同因素,如过度炎症反应以及对病原体严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的T细胞反应耗竭/抑制,这些因素与重症COVID-19相关。然而,从呼吸功能障碍的相关因素中筛选出致病因素仍处于初级阶段。
我们推测,导致呼吸功能障碍的宿主反应与疾病进展和缓解最为密切相关,因此可与其他与重症COVID-19有统计学关联但非致病的因素区分开来。为了追踪所涉及的宿主反应的时间动态,我们在涵盖呼吸功能最低点的15个不同时间点,检测了6例重症和4例非重症COVID-19患者全血中的基因表达变化。
我们发现,中性粒细胞激活而非I型干扰素信号转录本与疾病进展和缓解最为密切相关。此外,编码蛋白质磷酸化的转录本,特别是丝氨酸 - 苏氨酸激酶,其中许多具有已知的T细胞增殖和激活功能,在呼吸功能上升之前增加,因此可能有助于呼吸功能的上升。值得注意的是,这些相关基因是地塞米松的作用靶点,而非甲泼尼龙的作用靶点,这与临床试验中的疗效结果一致。
我们的研究结果表明,中性粒细胞激活是COVID-19呼吸功能障碍的关键因素。针对该途径的药物可能有潜力重新用于治疗重症COVID-19。
本研究部分由The Hour Glass的慷慨捐赠资助。EEO和JGL由新加坡国家医学研究理事会资助,通过新加坡国家研究基金会颁发的临床科学家奖获得资金。